Immunofan, rectal 90 mcg 5 pcs

Imunofan – detoxifying, hepatoprotective, antioxidant, immunomodulatory.

Pharmacodynamics

The drug has immune-regulating, detoxifying, hepatoprotective effect and causes inactivation of free radical and peroxide compounds. It corrects the state of the immune system, restores the balance of oxidation-antioxidant reactions of the body and promotes overcoming of multiple drug resistance of tumor cells, mediated by proteins of the cell transmembrane transport pump.

The action of the drug starts within 2-3 hours (fast phase) and lasts up to 4 months (middle and slow phases).

In the middle phase (begins after 2-3 days, duration – up to 7-10 days) there is an increase of phagocytosis reactions and death of intracellular bacteria and viruses.

In the slow phase (starts after 7-10 days, duration – up to 4 months) the immunoregulatory action of Imunofan® manifests itself – restoration of disturbed indices of cellular and humoral immunity. During this period, normalization of immunoregulatory index is observed, increased production of specific antibodies is noted. Influence of the drug on production of specific antiviral and antibacterial antibodies is equivalent to the action of therapeutic vaccines. Unlike the latter the preparation does not influence significantly on production of reactive antibodies of IgE class and does not strengthen reaction of immediate hypersensitivity type; Immunofan® stimulates production of IgA at its congenital insufficiency.

Inmunophan® effectively suppresses multiple drug resistance of tumor cells and increases their sensitivity to the action of chemotherapeutic agents.

Indications

For adults and children over 2 years of age (prevention and treatment):
immunodeficiency and toxic conditions;
chronic inflammatory diseases of various etiologies.
For adults – as an adjuvant for vaccination against bacterial and viral infections.

Pharmacological effect

Imunofan – detoxifying, hepatoprotective, antioxidant, immunomodulatory.

Pharmacodynamics

The drug has an immunoregulatory, detoxifying, hepatoprotective effect and causes inactivation of free radicals and peroxide compounds. Corrects the state of the immune system, restores the balance of the body’s oxidative-antioxidative reactions and helps overcome multidrug resistance of tumor cells, mediated by proteins of the cell’s transmembrane transport pump.

The effect of the drug begins to develop within 2–3 hours (fast phase) and lasts up to 4 months (medium and slow phases).

During the fast phase (duration – up to 2-3 days), the detoxification effect is manifested primarily – the body’s antioxidant defense is enhanced due to stimulation of the production of ceruloplasmin, lactoferrin, and catalase activity; the drug normalizes lipid peroxidation, inhibits the breakdown of cell membrane phospholipids and the synthesis of arachidonic acid, with a subsequent reduction in blood cholesterol levels and the production of inflammatory mediators. In case of toxic and infectious liver damage, the drug prevents cytolysis, reduces the activity of transaminases and the level of bilirubin in the blood serum.

During the middle phase (begins after 2-3 days, duration – up to 7-10 days), the reactions of phagocytosis and death of intracellular bacteria and viruses intensify.

During the slow phase (begins to develop on 7–10 days, duration up to 4 months), the immunoregulatory effect of Imunofan® is manifested – restoration of impaired indicators of cellular and humoral immunity. During this period, normalization of the immunoregulatory index is observed, and an increase in the production of specific antibodies is noted. The effect of the drug on the production of specific antiviral and antibacterial antibodies is equivalent to the effect of therapeutic vaccines. Unlike the latter, the drug does not have a significant effect on the production of reagin antibodies of the IgE class and does not enhance the immediate hypersensitivity reaction; Imunofan® stimulates the formation of IgA in case of congenital deficiency.

Imunofan® effectively suppresses multidrug resistance of tumor cells and increases their sensitivity to the effects of chemotherapy drugs.

Special instructions

As a result of activation of phagocytosis, a short-term exacerbation of foci of chronic inflammation, maintained due to the persistence of viral or bacterial antigens, is possible.

Active ingredient

Arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine

Composition

Suppositories for rectal use 1 sup. imunofan 100 mcg

excipients:

purified water;

glycine;

hard fat;

twin 80

Pregnancy

Due to insufficient knowledge, it should be used with caution during pregnancy and lactation.

Contraindications

Hypersensitivity; children under 2 years of age.

Side Effects

Possible: individual intolerance, allergic reactions.

Interaction

Increases the effectiveness of other types of drug therapy: the use of imunofan helps overcome resistance to glucocorticosteroid therapy.

The drug can be prescribed in combination with anti-inflammatory steroidal and non-steroidal anti-inflammatory drugs.

Storage conditions

The drug is stored in a place protected from light at a temperature of 2°C to 10°C, out of the reach of children.

Shelf life

2 years.

Manufacturer

Bionox, Russia